Survey says: Nissen or Rost for FDA Commish

Steven Nissen (photo) may be on Big Pharma's short list for the least desirable candidate for  FDA Commissioner, but many apparently think its critics like him who should be at the top of the list. That's according to a survey conducted by Pharma Marketing News. Nearly 500 respondents weighed in with their picks for who should be nominated as FDA Commissioner. The survey asked for opinions for 10 potentials usually mentioned in the media. Peter Rost took first place, Steven Nissen came in at second, with Susan Wood in third. Janet Woodcock and Robert Califf tied for fourth place.

Survey respondents included pharma industry execs and staff, agents and vendors to the industry, healthcare professionals, government staff and readers from the general public. Interestingly, although Rost was favored overall, Nissen was favored among US respondents. But broken down by industry, the results showed that Pharma in particular favored FDA insiders Woodcock and David Kessler, while healthcare professionals supported Nissen and the general public preferred Rost.

- check out the Pharma Marketing News post
- view the survey results (.pdf)

Suggested Articles

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.